Eisai

Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050

Retrieved on: 
Wednesday, February 21, 2024

TOKYO, Feb 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval to participate in the Japan Climate Initiative (JCI) Race to Zero Circle, which commits to achieve net zero* by 2050, as part of its mid- and long-term initiatives to reduce greenhouse gas (GHG) emissions.

Key Points: 
  • TOKYO, Feb 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval to participate in the Japan Climate Initiative (JCI) Race to Zero Circle, which commits to achieve net zero* by 2050, as part of its mid- and long-term initiatives to reduce greenhouse gas (GHG) emissions.
  • Eisai also received approval for the SBT 1.5degC target, a new GHG reduction target, by "Science Based Targets (SBT) initiatives", as outlined below.
  • In order to achieve Net Zero by 2050, Eisai continues to strengthen its GHG reduction initiatives though the JCI Race to Zero Circle and the newly approved SBT 1.5degC target, as well as our continued commitment to the global initiative RE100.
  • Neutralizing any residual emissions at the net-zero target year and any GHG emissions released into the atmosphere thereafter.

Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives

Retrieved on: 
Tuesday, February 20, 2024

TOKYO, Feb 20, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for "Human Capital Leaders 2023" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2023" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.) and MS&AD InterRisk Research & Consulting, Inc.

Key Points: 
  • TOKYO, Feb 20, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for "Human Capital Leaders 2023" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2023" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.) and MS&AD InterRisk Research & Consulting, Inc.
  • In the "Human Capital Survey 2023" (conducted between September and December 2023), 16 highly rated companies were selected for "Human Capital Management Gold Quality", and 8 companies that were recognized by experts as having made particularly outstanding efforts were selected as "Human Capital Leaders 2023" out of approximately 500 participating companies and organizations.
  • Moreover, Eisai published the "Human Capital Report 2023" (PDF) in July, 2023 that summarizes its human capital initiatives and KPI linked to its human resource strategies.
  • Eisai promotes information disclosure regarding its initiatives on human capital management in its annual "Value Creation Report(PDF)" and on its corporate website's "Sustainability" section.

Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan

Retrieved on: 
Friday, February 16, 2024

TOKYO, Feb 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate).

Key Points: 
  • TOKYO, Feb 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate).
  • Based on the license agreement signed by Eisai and medac GmbH in May 2019, nippon medac will hold the marketing authorization of Metoject, while Eisai will be responsible for product distribution of Metoject in Japan.
  • This formulation incorporates the previously MHLW-approved Metoject Subcutaneous Injection pre-filled syringe formulation in a pen-type autoinjector and was developed to reduce the burden on patients and improve safety during self-injection.
  • The drug can be self-injected in two steps (1- removing the cap, 2- pressing the pen against the skin).

PRIME® Study on Real-World Disparities in LGBTQ+ Cancer Care Wins Prestigious William Campbell Felch Award

Retrieved on: 
Tuesday, February 6, 2024

This marks the third time PRIME has won the award in the last five years.

Key Points: 
  • This marks the third time PRIME has won the award in the last five years.
  • PRIME’s research-driven initiative was designed to identify and address real-world disparities in LGBTQ+ cancer care and drive sustainable change in practice across oncology care settings.
  • This landmark initiative demonstrates how utilizing real-world patient insights and research-driven education can be a sustainable catalyst for advancing equitable cancer care.
  • We are honored that this important work has been recognized through the prestigious Felch award," says Chris Napolitan, Managing Director of PRIME.

Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis

Retrieved on: 
Friday, January 26, 2024

TOKYO, Jan 26, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan.

Key Points: 
  • TOKYO, Jan 26, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan.
  • In May 2022, ultrahigh-dose mecobalamin received orphan drug designation by the Ministry of Health, Labour and Welfare (MHLW).
  • The results of JETALS were published in the peer-reviewed journal JAMA Neurology.
  • ALS is an intractable, progressive, neurodegenerative disease that results in severe muscle atrophy and weakness in the muscles due to motor neuron dysfunction.

Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan

Retrieved on: 
Thursday, January 18, 2024

TOKYO, Jan 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.

Key Points: 
  • TOKYO, Jan 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.
  • Fycompa is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories.
  • Two oral formulations of Fycompa are available in Japan: a tablet and a fine granule formulation.
  • Since Fycompa is the only AMPA receptor antagonist-based AED, Eisai developed this injection formulation to meet the needs of patients who are unable to use oral administration, and filed a supplementary new drug application as a new route of administration in August 2022, leading to this approval.

Biogen to Realign Resources for Alzheimer's Disease Franchise

Retrieved on: 
Wednesday, January 31, 2024

CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth.
  • A large portion of the resources released resulting from termination of the ADUHELM program will be redeployed in Biogen’s AD franchise.
  • “As a pioneer in Alzheimer’s disease, Biogen is reprioritizing resources to build a leading franchise to address the multiple pathologies of the disease and patient needs.
  • Biogen has recorded a one-time charge of approximately $60 million related to close out costs for the program in the fourth quarter of 2023.

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Retrieved on: 
Tuesday, January 30, 2024

to include the pancreatic cancer indication of Can-Fite.

Key Points: 
  • to include the pancreatic cancer indication of Can-Fite.
  • Ewopharma AG exercised its right to expand the distribution agreement to include the indication of pancreatic cancer and the transaction terms of the distribution agreement are applicable to such indication.
  • In addition to Can-Fite, Ewopharma AG has distribution agreements with many leading healthcare companies including Eisai and Biogen.
  • “We are very pleased to expand the distribution agreement with Ewopharma, a leader in pharmaceutical distribution in Central Eastern Europe and Switzerland and include the pancreatic cancer indication.

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy

Retrieved on: 
Saturday, January 27, 2024

At 48 months, the estimated OS rate was 91.2% for patients who received KEYTRUDA compared to 86.0% for patients who received placebo.

Key Points: 
  • At 48 months, the estimated OS rate was 91.2% for patients who received KEYTRUDA compared to 86.0% for patients who received placebo.
  • Treatment-related adverse events (TRAEs) occurred in 79.1% of patients (n=386) in the KEYTRUDA arm and 53.0% of patients (n=263) in the placebo arm.
  • Grade 3-4 TRAEs occurred in 18.6% of patients in the KEYTRUDA arm and 1.2% of patients in the placebo arm.
  • Treatment-related adverse events resulting in discontinuation of any treatment occurred in 18.2% of patients in the KEYTRUDA arm and 0.8% of patients in the placebo arm.

Eisai Aims to Advance Genitourinary Cancer Treatment with New Research at ASCO GU 2024

Retrieved on: 
Thursday, January 18, 2024

NUTLEY, N.J., Jan. 18, 2024 /PRNewswire/ --  Eisai announced today the presentation of research in renal cell carcinoma (RCC) during the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (#GU24) which is taking place in-person in San Francisco, California and online from January 25-27. Notable presentations include a rapid oral abstract session featuring subgroup analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which evaluated lenvatinib (LENVIMA®), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus pembrolizumab (KEYTRUDA®), Merck's anti-PD-1 therapy, versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (aRCC) (NCT02811861; Abstract: #364).

Key Points: 
  • We look forward to engaging in critical scientific exchange to improve outcomes for these patients."
  • A network meta-analysis to assess the efficacy of lenvatinib plus pembrolizumab compared with other first-line treatment options for patients with aRCC will be shared in a poster session (Abstract: #482).
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • These abstracts will be made available via the ASCO website on Monday, January 22, 2024, at 5:00 PM EST (2:00 PM PST).